Merck ’s letermovir meets primary endpoint in Phase III trial to prevent CMV infection

Healthcare firm Merck has reported positive results from the Phase III clinical trial of anti-viral drug letermovir to prevent cytomegalovirus (CMV) infection in recipients of bone marrow transplant.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news